VTVT 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-08-06

• There have been no material developments since our last reporting period.

• materials. Our indirect research and development costs consist primarily of cash and share-based compensation costs, the cost of employee benefits and related overhead expenses for personnel in research and development functions. Since we typically use our employee and infrastructure resources acros…

• Our research and development expenses by project for the three and six months ended June 30, 2026 and 2025 were as follows (in thousands):

• Less: net loss attributable to noncontrolling interest—(1,334)1,334

• There was no revenue for the three months ended June 30, 2026 and 2025.

相对上期删除的文字 · 来源:10-Q · 2026-05-13

• In January 2026, the Company entered into the Second Amendment to License Agreement (the "Second Amendment") to provide Newsoara Biopharma Co., Ltd. (“Newsoara”) with global rights to HPP737. In exchange for the global rights, Newsoara paid the Company an upfront amount of $20.0 million and agreed t…

• Under the terms of the Newsoara License Agreement, Newsoara will be responsible for the development and commercialization of the licensed products at its cost, and is required to use commercially reasonable efforts with respect to such development and commercialization efforts.

• Our research and development expenses by project for the three months ended March 31, 2026, and 2025 were as follows (in thousands):

• in any of our clinical trials, we could be required to expend significant additional financial resources and time with respect to the development of that drug candidate.

• Comparison of the three months ended March 31, 2026, and 2025

相对上期新增的文字 · 来源:10-Q · 2026-08-06

• same business day as the filing date with the SEC on the SEC’s website http://www.sec.gov. The contents of our website are not made a part of this Quarterly Report on Form 10-Q.

相对上期删除的文字 · 来源:10-Q · 2026-05-13

• compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and may not be detected.